Patsner B, Mann W J, Vissicchio M, Loesch M
Department of Obstetrics and Gynecology, State University of New York, School of Medicine, Stony Brook 11794-8091.
Gynecol Oncol. 1988 May;30(1):98-103. doi: 10.1016/0090-8258(88)90051-0.
Twenty-seven patients with frankly invasive nonmucinous invasive adenocarcinoma of the ovary were monitored using a serial CA-125 and lipid-associated sialic acid (LASA-P) levels prior to cytoreductive surgery, during chemotherapy, before second-look surgery or disease progression, and during subsequent follow-up. All levels were measured using previously described techniques. Serum LASA-P levels correlated well with CA-125 levels during all phases of treatment with no significant difference in predictive value of elevated or normal levels. LASA-P levels, thus, offer another, possibly less expensive, method of monitoring patients with invasive ovarian adenocarcinoma during therapy and in predicting the likelihood of a positive second-look laparotomy.
对27例确诊为卵巢非黏液性浸润性腺癌的患者，在肿瘤细胞减灭术前、化疗期间、二次探查手术或疾病进展前以及后续随访期间，采用连续检测CA - 125和脂质相关唾液酸（LASA - P）水平的方法进行监测。所有检测均采用先前描述的技术。在治疗的各个阶段，血清LASA - P水平与CA - 125水平密切相关，升高或正常水平的预测价值无显著差异。因此，LASA - P水平为监测浸润性卵巢腺癌患者的治疗过程及预测二次剖腹探查阳性的可能性提供了另一种可能成本较低的方法。
